Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Phase II Chemotherapy with YOSHI-864 for Carcinoma of the Cervix, Endometrium, or Ovary

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Closed

no age specified

MDA-G-7805

Objectives

I.  Determine the activity of Yoshi-864 in selected patients with carcinoma of 
the cervix, endometrium, or ovary.
II.  Further investigate the toxicity of this drug following irradiation 
therapy, chemotherapy, abdominal surgery or a combination of these treatments.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with histologically proven 
measurable carcinoma of the cervix or endometrium who are not eligible for 
radiotherapy or surgery and who have failed prior chemotherapy, or patients 
with adenocarcinoma of the ovary Stages III or IV who have failed to respond 
to 1st and 2nd line chemotherapy programs.  Patients must have adequate 
hematologic, liver, and kidney function.  All prior therapy must have 
terminated at least 4 weeks prior to study entry and patients must have 
recovered from the toxic effects.

Expected Enrollment

52 patients will be entered in 9 months.  Protocol closed.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Yoshi-864, YOSHI, NSC-102627.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Eugene M. McKelvey, MD, Protocol chair
Ph: 713-792-2570; 800-392-1611

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.